Drug Profile
Research programme: small molecule therapeutics - Genentech/Vernalis
Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Genentech; Vernalis
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in United Kingdom
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA